Beta Bionics, Inc. - Common Stock, $0.0001 par value per share (BBNX)

CUSIP: 08659B102

Q2 2026 13F Holders as of 30 Jun 2026

Holder snapshot 6 signals
Share change
-412,649
SEC-reported price per share
$15.67
Number of holders
9
Value change
-$6,465,745
Number of buys
3
Number of sells
5
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
44,369,313

Security key

08659B102

Report period

Q2 2026

Institutions

9

Top holders

9

Ownership snapshot

Top reported holders of BBNX - Beta Bionics, Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
EVENTIDE ASSET MANAGEMENT...
Disclosed value leader
Zone Healthcare Holdings,...
Comparable rows
15/15
Latest evidence
21 May 2026
13F 13D/G 3/4/5 Lead comparable stake: 13% 13D/G row: EVENTIDE ASSET MANAGEMENT, LLC Showing 1-6 of 15 holder rows.

Quick read

EVENTIDE ASSET MANAGEMENT, LLC leads the comparable SEC ownership view at 13%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens EVENTIDE ASSET MANAGEMENT, LLC's linked filing trail.
Comparable ownership Top 5
EVENTIDE ASSET MANAGEMENT, LLC 13%
Zone Healthcare Holdings, LLC 9.9%
Soleus Capital Group, LLC 9.8%
MORGAN STANLEY 8.6%
Sands Capital Life Sciences Pulse... 8.2%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
EVENTIDE ASSET MANAGEMENT, LLC
13F 13D/G
Company
13%
from 13D/G
$59,567,287
5,945,488 shares
31 Mar 2026
Zone Healthcare Holdings, LLC
13D/G
Dapice Joshua J.
9.9%
$85,717,590
4,313,920 shares
+$17,618,729 30 Sep 2025
Soleus Capital Group, LLC
13D/G
Levy Guy
9.8%
$38,580,879
4,354,501 shares
$0 31 Mar 2026
MORGAN STANLEY
13D/G 13F
Company
8.6%
$74,305,196
3,739,567 shares
+$16,109,185 30 Sep 2025
Sands Capital Life Sciences Pulse Fund II, L.P.
13D/G
8.2%
$48,410,732
3,570,113 shares
+$5,636,946 30 Jun 2025
Farallon Capital Partners, L.P.
13D/G
Dapice Joshua J.
8.1%
$31,966,171
3,607,920 shares
-$6,839,920 31 Mar 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2026

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
9
Shares
126,983
Rows available
9
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q2 2026 vs Q1 2026 Across Filers

Q1 2026 holders
128
Q2 2026 holders
9
Holder diff
-119
Investor Q1 2026 Shares Q2 2026 Shares Share Diff Share Chg % Q1 2026 value Q2 2026 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .